Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.
BACKGROUND
We report a case of a patient with recurrent severe hypoglycemia after initiating the drug rasagiline (Azilect) for Parkinson disease.


METHODS
A 25-year-old Emirati woman who had been diagnosed with Parkinson disease due to a genetic mutation since the age of 18 years presented to our hospital. She had been treated with a rotigotine patch 2 mg per day along with carbidopa + levodopa + entacapone 25 mg/100 mg/200 mg (Stalevo) over these years. Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor). Soon after this change, she started experiencing recurrent documented severe hypoglycemia requiring hospitalization. Her hypoglycemic symptoms completely disappeared after 5-7 days of drug withdrawal. Despite detailed evaluation, no other causal relationship was documented except for rasagiline.


CONCLUSIONS
To the best of our knowledge, this case report documents an unknown association between rasagiline and hypoglycemia.
Endocrine Division, Dubai Hospital, Dubai, United Arab Emirates. ibrahimfawzi@yahoo.com.
Fawzi A Bachet
FA
Ibrahim
Endocrine Division, Dubai Hospital, Dubai, United Arab Emirates.
Fauzia
F
Rashid
Endocrine Division, Dubai Hospital, Dubai, United Arab Emirates.
Azza A Bin
AA
Hussain
Endocrine Division, Dubai Hospital, Dubai, United Arab Emirates.
Fatheya
F
Alawadi
Endocrine Division, Dubai Hospital, Dubai, United Arab Emirates.
A
A
Bashier
D000328:Adult; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007189:Indans / Q000009:adverse effects*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*
D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline
Case report; Diabetes; Hypoglycemia; MAO inhibitor; Parkinson disease; Rasagiline; SSRI